Loading patent…
OwnerKathleen E. CLARENCE-SMITHinventor
Estimating the term…
A pharmaceutical combination includes a beta-lactam antibiotic alone or in combination with a beta-lactamase inhibitor useful for treating multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma. A method for treating multiple myeloma, monoclonal gammopathy of undetermined significance, or smoldering multiple myeloma includes administering to a patient in need thereof an effective amount of a combination of a beta-lactam antibiotic and a beta-lactamase 2024/102361 inhibitor. Beta-lactam antibiotic for use in combination with a beta-lactamase inhibitor for the treatment of multiple myeloma, monoclonal gammopathy of undetermined significance, or smoldering multiple myeloma in a patient in need of the treatment is also described.
A method for treating multiple myeloma, monoclonal gammopathy of undetermined significance, or smoldering multiple myeloma, comprising administering to a patient in need thereof an effective amount of a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor.
19-30. (canceled)
A pharmaceutical combination comprising a beta-lactam antibiotic and a beta-lactamase inhibitor for use in the treatment of multiple myeloma, monoclonal gammopathy of undetermined significance, or smoldering multiple myeloma.
A method for treating multiple myeloma, monoclonal gammopathy of undetermined significance, or smoldering multiple myeloma in a patient, comprising identifying a germ which is causing the multiple myeloma, monoclonal gammopathy of undetermined significance, or smoldering multiple myeloma in the patient, and then administering to the patient an effective amount of an antibiotic against that germ.
Dependencies are inferred from the claim text.